Oh, and as far as VRX developing a drug anytime soon....
$VRX says it paid off $3.6B debt since Q116; if so debt down11%. But EBITDA down 20%+ so lev indicated 7x or worse. https://t.co/gBh3i6fiE1
— Vicki Bryan’s Bond Angle (@VickiBryanBondA) May 1, 2017
$VRX Motions to dismiss the Philidor Class Action (Potter) fail, litigation full steam ahead, court memorandum no bueno for damages pic.twitter.com/zvRLxOmbgy